Compare Biogen Inc (BIIB) vs Invesco WilderHill Clean Energy ETF (PBW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Invesco WilderHill Clean Energy ETF — how do they compare? Biogen Inc trades at $207.48 (market cap $30.13B), while Invesco WilderHill Clean Energy ETF trades at $34.8. The key difference: Biogen Inc is trading nearer its 52-week high, Invesco WilderHill Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | PBW | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $216.63 | $46.99 |
52-Week Low | $128.93 | $24.14 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
PBW trades at $34.93, up 0.92% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF benefits from clean energy tailwinds, including rising global investment and energy security concerns, yet lacks disclosed fundamental ratios. Recent news highlights volatility linked to interest rate movements and sector rotations.
Outlook is mixed: clean energy demand offers growth potential, but sensitivity to Treasury yields and tech sell-offs poses risks. Investors face upside from policy support offset by macroeconomic headwinds and valuation uncertainties due to missing financial data.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →
